Pacific Biosciences Of California Net Debt Growth & History (PACB)
Pacific Biosciences Of California's net debt was −$6.7M for fiscal 2025.
View full Pacific Biosciences Of California company overviewPacific Biosciences Of California annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$6.7M | $23.8M | — |
| 2024 | 2024-12-31 | −$30.4M | $107.8M | — |
| 2023 | 2023-12-31 | −$138.2M | −$761.6M | — |
| 2022 | 2022-12-31 | $623.4M | $128.8M | +26.03% |
| 2021 | 2021-12-31 | $494.6M | $534.2M | — |
| 2020 | 2020-12-31 | −$39.6M | −$71.7M | — |
| 2019 | 2019-12-31 | $32.0M | $36.2M | — |
| 2018 | 2018-12-31 | −$4.2M | −$1.3M | — |
| 2017 | 2017-12-31 | −$2.9M | −$2.2M | — |
| 2016 | 2016-12-31 | −$659,000 | — | — |
| 2014 | 2014-12-31 | −$19.9M | −$9.5M | — |
| 2013 | 2013-12-31 | −$10.4M | $30.6M | — |
| 2012 | 2012-12-31 | −$41.0M | $15.0M | — |
| 2011 | 2011-12-31 | −$55.9M | $88.7M | — |
| 2010 | 2010-12-31 | −$144.6M | — | — |
Pacific Biosciences Of California quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $792,000 | $2.8M | — |
| Q1 2026 | 2026-03-31 | $3.0M | $8.6M | — |
| Q4 2025 | 2025-12-31 | −$6.7M | $23.8M | — |
| Q3 2025 | 2025-09-30 | −$1.5M | $48.8M | — |
| Q2 2025 | 2025-06-30 | −$2.0M | $65.4M | — |
| Q1 2025 | 2025-03-31 | −$5.6M | $32.2M | — |
| Q4 2024 | 2024-12-31 | −$30.4M | $107.8M | — |
| Q3 2024 | 2024-09-30 | −$50.4M | $291.7M | — |
| Q2 2024 | 2024-06-30 | −$67.4M | $96.0M | — |
| Q1 2024 | 2024-03-31 | −$37.8M | −$628.8M | — |
| Q4 2023 | 2023-12-31 | −$138.2M | −$761.6M | — |
| Q3 2023 | 2023-09-30 | −$342.1M | −$986.0M | — |
| Q2 2023 | 2023-06-30 | −$163.4M | −$803.2M | — |
| Q1 2023 | 2023-03-31 | $591.0M | $67.5M | +12.90% |
| Q4 2022 | 2022-12-31 | $623.4M | $128.8M | +26.03% |
| Q3 2022 | 2022-09-30 | $643.9M | $116.3M | +22.04% |
| Q2 2022 | 2022-06-30 | $639.8M | $163.7M | +34.39% |
| Q1 2022 | 2022-03-31 | $523.4M | $519.2M | +12336.26% |
| Q4 2021 | 2021-12-31 | $494.6M | $534.2M | — |
| Q3 2021 | 2021-09-30 | $527.6M | $553.6M | — |
| Q2 2021 | 2021-06-30 | $476.0M | $475.4M | +76188.94% |
| Q1 2021 | 2021-03-31 | $4.2M | $28.2M | — |
| Q4 2020 | 2020-12-31 | −$39.6M | −$71.7M | — |
| Q3 2020 | 2020-09-30 | −$26.0M | −$55.2M | — |
| Q2 2020 | 2020-06-30 | $624,000 | −$31.8M | −98.08% |
| Q1 2020 | 2020-03-31 | −$24.0M | −$49.1M | — |
| Q4 2019 | 2019-12-31 | $32.0M | $36.2M | — |
| Q3 2019 | 2019-09-30 | $29.2M | $52.8M | — |
| Q2 2019 | 2019-06-30 | $32.4M | $41.4M | — |
| Q1 2019 | 2019-03-31 | $25.1M | $36.7M | — |
| Q4 2018 | 2018-12-31 | −$4.2M | −$1.3M | — |
| Q3 2018 | 2018-09-30 | −$23.7M | — | — |
| Q2 2018 | 2018-06-30 | −$8.9M | — | — |
| Q1 2018 | 2018-03-31 | −$11.6M | — | — |
| Q4 2017 | 2017-12-31 | −$2.9M | −$2.2M | — |
| Q4 2016 | 2016-12-31 | −$659,000 | — | — |
| Q4 2014 | 2014-12-31 | −$19.9M | −$9.5M | — |
| Q4 2013 | 2013-12-31 | −$10.4M | $30.6M | — |
| Q1 2013 | 2013-03-31 | −$50.3M | $3.1M | — |
| Q4 2012 | 2012-12-31 | −$41.0M | $15.0M | — |
| Q3 2012 | 2012-09-30 | −$29.7M | $24.9M | — |
| Q2 2012 | 2012-06-30 | −$30.8M | $20.8M | — |
| Q1 2012 | 2012-03-31 | −$53.4M | — | — |
| Q4 2011 | 2011-12-31 | −$55.9M | $88.7M | — |
| Q3 2011 | 2011-09-30 | −$54.6M | — | — |
| Q2 2011 | 2011-06-30 | −$51.5M | — | — |
| Q4 2010 | 2010-12-31 | −$144.6M | — | — |
Pacific Biosciences Of California net debt trends
Over the last five fiscal years, Pacific Biosciences Of California's net debt increased from −$39.6M to −$6.7M, a change of $32.9M. The latest reported quarter, Q2 2026, shows $792,000.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pacific Biosciences Of California source filings ↗